PV Bulletin

Draft Guidance for Biosimilar and Interchangeable Biosimilar Products: Container Closure Systems

The FDA's draft guidance provides recommendations for container closure systems and device constituent parts for biosimilar products, emphasizing the importance of user interface evaluations.

Primary source: View printed version (PDF)

PV Impact Brief

Urgency: HighConfidence: high

What changed

The FDA has provided specific recommendations for the development of container closure systems and device constituent parts for biosimilar products, including the need for user interface evaluations.

Why it matters

Ensuring the safety and efficacy of biosimilar products is critical, particularly as differences in delivery systems can introduce new risks. Adhering to this guidance helps mitigate potential user errors and device-related adverse events.

Action needed

Stakeholders involved in biosimilar product development must review the draft guidance, focus on comparative safety assessments, and submit relevant comments by the deadline of October 2, 2026.

Relevant for
Regulatory Intelligence LeadSignal Management LeadQPPV
Processes impacted
Signal ManagementCountry Compliance
Owner

Regulatory Intelligence Lead

Review cadence

Review before 2026-10-02.

Policy change details

Document type
Draft Guidance
Policy status
draft
Publication date
2026-08-03
Consultation deadline
2026-10-02
Policy change
This draft guidance provides recommendations for developing container closure systems (CCS) and device constituent parts for proposed biosimilar and interchangeable biosimilar products, particularly for combination products. It expands on earlier Q&A guidance by clarifying FDA's expectations for comparative assessments and the evaluation of the user interface to ensure safety and effectiveness. The document outlines the quality data and human factors studies required when the delivery device for a biosimilar differs from the reference product.

Key changes

Named sections on product quality considerations for CCS and delivery devices, expectations for user interface evaluation (human factors studies), and data requirements for demonstrating that differences in the device do not impact safety or efficacy for the intended user population.

Affected workflows

Signal ManagementCountry Compliance

Responsible groups

SponsorsClinical SafetyRegulatory Affairs

Document identifiers

FDA-2026-D-4272

PV impact

Pharmacovigilance and clinical safety teams must review the guidance to ensure that comparative safety assessments for biosimilar delivery devices adequately address potential user errors and device-related adverse events. For interchangeable products, specific attention is required for the user interface to ensure that switching from the reference product does not introduce new safety risks. Sponsors should update their development protocols and RMPs to include these comparative device assessments.

View regulator source

Source document details

Exact policy details

Comments Deadline
October 2, 2026
Applies to: All stakeholders involved in biosimilar and interchangeable biosimilar product development
Comments are being accepted until October 2, 2026, to ensure agency consideration before final guidance work begins. · p. 1 · High · Source
Guidance for Development
Draft guidance on container closure systems for biosimilar products
Applies to: Developers of biosimilar and interchangeable biosimilar products
The draft guidance is intended to help applicants develop container closure systems and device constituent parts for proposed biosimilar products. · p. 1 · High · Source

Extracted documents

Evidence and confidence

Confidence: highSource updated: Aug 3, 2026

Full briefing

Practical implication

Stakeholders involved in biosimilar product development must review the draft guidance, focus on comparative safety assessments, and submit relevant comments by the deadline of October 2, 2026.

The FDA released a draft guidance for industry entitled 'Biosimilar and Interchangeable Biosimilar Products: Considerations for Container Closure Systems and Device Constituent Parts.' The draft outlines expectations for developing container closure systems and delivery devices for biosimilar and interchangeable products. It specifies that comparative assessments should ensure safety and effectiveness, especially focusing on the user interface in case of differences from reference products. Stakeholders must submit comments by October 2, 2026.

What changed: The FDA has provided specific recommendations for the development of container closure systems and device constituent parts for biosimilar products, including the need for user interface evaluations.

Why it matters: Ensuring the safety and efficacy of biosimilar products is critical, particularly as differences in delivery systems can introduce new risks. Adhering to this guidance helps mitigate potential user errors and device-related adverse events.

Practical implication: Stakeholders involved in biosimilar product development must review the draft guidance, focus on comparative safety assessments, and submit relevant comments by the deadline of October 2, 2026.

View original source

Published from the Firecrawl policy change extraction pipeline.

#Safety Signals#Reporting Requirement#policy-change#firecrawl-policy-agent#Food and Drug Administration#Draft Guidance#draft

Related updates for your role

publicFDA · USA · Updated Sep 4, 2026

FDA Grants Accelerated Approval to Etcamah for Advanced Breast Cancer

Urgency: High

Regulatory teams must prepare for updating labeling to include details on the new indication and required diagnostic methods, along with planning for the confirmatory studies mandated by the FDA.

Signal ManagementLabelingRegulatory Intelligence Lead
SOP Impact2 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicMHRA · UK · Updated Sep 4, 2026

Change to the definition of regulated activity with children from 1 September 2026

Urgency: High

Organizations must re-evaluate roles related to children's activities and prepare to request Enhanced DBS checks including access to the Children’s Barred List check starting from 1 September 2026.

Country ComplianceRegulatory Intelligence Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: Regulatory Intelligence Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicUK Health Security Agency · UK · Updated Sep 7, 2026

Low Flu Vaccination Rates Among Primary School Children

Urgency: High

Parents are reminded to complete and return flu vaccination consent forms promptly as vaccination sessions in schools are set to start this week, aiming for completion by late November.

Signal ManagementPV Quality Lead
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: PV Quality Lead, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward
publicANSM (France) · France · Updated Sep 7, 2026Translated From French

Recall of Gore Viabahn Endoprosthesis with Bioactive Heparin Coating

Urgency: High

Health establishments receiving affected devices must be notified, and protocols established to ensure compliance with the recall.

Signal ManagementQPPV
SOP Impact1 SOPs
ConfidenceHigh
Relevant for: QPPV, Medical Safety Lead
verifiedRegulatory action: Regulators
Read impact briefarrow_forward